What are generic alternatives to Mounjaro?
As of late 2023 and heading into 2025, there are no generic alternatives to Mounjaro (tirzepatide) available on the market [1]. Mounjaro is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist [2].
When might generic Mounjaro become available?
The availability of generic versions of a drug is tied to patent expirations and exclusivities. For Mounjaro, the earliest patent expiry dates are not until 2027, with some extending to 2037 [3]. DrugPatentWatch.com tracks these patent situations, and the earliest opportunities for generic Mounjaro to enter the market would likely be after these patent protections have lapsed [3].
What other drugs work like Mounjaro?
Other medications that target the GLP-1 receptor are available, though they do not have the dual GIP/GLP-1 action of Mounjaro. These include:
* Ozempic (semaglutide): A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management [4].
* Wegovy (semaglutide): A higher-dose formulation of semaglutide also approved for chronic weight management [4].
* Trulicity (dulaglutide): Another GLP-1 receptor agonist for type 2 diabetes [5].
* Victoza (liraglutide): A GLP-1 receptor agonist indicated for type 2 diabetes and to reduce cardiovascular risk in adults with type 2 diabetes and established cardiovascular disease [6].
* Rybelsus (semaglutide): An oral formulation of semaglutide for type 2 diabetes [4].
These GLP-1 receptor agonists may offer similar weight loss and blood sugar control benefits to Mounjaro, although Mounjaro has demonstrated superior efficacy in clinical trials for both type 2 diabetes and weight loss due to its dual mechanism of action [2].
What is Mounjaro used for?
Mounjaro is indicated for the treatment of type 2 diabetes mellitus in adults, along with diet and exercise, to improve glycemic control [2]. It is also used for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity [2].
What is the difference between Mounjaro and Wegovy/Ozempic?
The primary difference lies in their mechanism of action. Mounjaro is a dual GIP and GLP-1 receptor agonist, meaning it activates two key incretin pathways involved in regulating blood sugar and appetite [2]. Wegovy and Ozempic are solely GLP-1 receptor agonists [4]. Clinical studies have shown that Mounjaro leads to greater reductions in A1C and body weight compared to semaglutide (the active ingredient in Wegovy and Ozempic) [2].
What are the side effects of Mounjaro?
Common side effects of Mounjaro include nausea, vomiting, diarrhea, constipation, and abdominal pain [2]. More serious, though less common, side effects can include pancreatitis, gallbladder problems, kidney problems, and thyroid tumors [2]. Patients are advised to discuss any concerns with their healthcare provider.
How much does Mounjaro cost?
The list price for Mounjaro can vary, but it is generally considered an expensive medication. For example, a 4-week supply can cost upwards of $1,000 to $1,100 without insurance or savings cards [1]. Costs can be significantly reduced for individuals with insurance coverage or through manufacturer savings programs.
---
Sources:
[1] DrugPatentWatch.com - https://www.drugpatentwatch.com/
[2] Eli Lilly and Company. MOUNJARO® (tirzepatide) Prescribing Information. 2023.
[3] DrugPatentWatch.com. Mounjaro patents. https://www.drugpatentwatch.com/ (Accessed November 2023)
[4] Novo Nordisk. Ozempic®, Wegovy®, Rybelsus® Prescribing Information. 2023.
[5] Eli Lilly and Company. TRULICITY® (dulaglutide) Prescribing Information. 2023.
[6] Novo Nordisk. Victoza® Prescribing Information. 2023.